Anti-COVID-19 Compound Library

Anti-COVID-19 Compound Library
Artikelnummer
MEXHY-L052-250
Verpackungseinheit
250 μl
Hersteller
MedChemExpress

Verfügbarkeit: wird geladen...
Preis wird geladen...
Description: COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.
COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.
Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1477 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.
MCE Anti-COVID-19 Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1449 compounds supplied in 10 mM solution, 25 compounds supplied in 2 mM solution and 3 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:
  • A unique collection of 1477 compounds that may have anti-COVID-19 activity for high throughput screening (HTS) and high content screening (HCS).
  • All compounds are derived from virtual screening of approved compound library and clinical compound library based on the 3CL protease, Spike Glycoprotein and ACE2 structure.
  • A useful tool for the development of anti-COVID-19 drugs.
  • Bioactivity and safety confirmed by preclinical research and clinical trials.
  • Structurally diverse, medicinally active, and cell permeable.
  • More detailed compound information with structure, IC50, and brief introduction.
  • NMR and HPLC validated to ensure high purity and quality.
  • All compounds are in stock and continuously updated.


Formulation: A collection of 1477 compounds that may have anti-COVID-19 activity supplied as pre-dissolved Solutions or SolidSolution:1449 compounds supplied in 10 mM solution,25 compounds supplied in 2 mM solution,3 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Mehr Informationen
Artikelnummer MEXHY-L052-250
Hersteller MedChemExpress
Hersteller Artikelnummer HY-L052-250
Green Labware Nein
Verpackungseinheit 250 μl
Mengeneinheit STK
Produktinformation (PDF)
×
MSDS (PDF)
×